Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor maintenance after combination chemotherapy in advanced or recurrent endometrial cancer
2017-000607-25Phase 3Active
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Selinexor maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival. Started Oct 2017; status: active.
02
Drugs
selinexor
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2017-000607-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000607-25.